- Home
- NMCO vs CRMD Comparison
NMCO vs CRMD Comparison
Compare NMCO & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NMCO | CRMD |
|---|---|---|
| Founded | N/A | 2006 |
| Country | United States | United States |
| Employees | N/A | 191 |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 560.1M | 509.9M |
| IPO Year | 2019 | 2009 |
Fundamental Metrics
Financial Performance| Metric | NMCO | CRMD |
|---|---|---|
| Price | $10.59 | $6.44 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $14.67 |
| AVG Volume (30 Days) | 136.4K | ★ 1.4M |
| Earning Date | 01-01-0001 | 06-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 780.00 |
| EPS | N/A | ★ 2.04 |
| Revenue | N/A | ★ $311,709,000.00 |
| Revenue This Year | N/A | $1.10 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $3.14 |
| Revenue Growth | N/A | ★ 617.03 |
| 52 Week Low | $9.69 | $5.60 |
| 52 Week High | $11.20 | $17.43 |
Technical Indicators
Market Signals| Indicator | NMCO | CRMD |
|---|---|---|
| Relative Strength Index (RSI) | 42.01 | 36.81 |
| Support Level | $10.44 | $6.13 |
| Resistance Level | $10.74 | $7.44 |
| Average True Range (ATR) | 0.10 | 0.30 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 25.58 | 22.81 |
Price Performance
Historical ComparisonAbout NMCO Nuveen Municipal Credit Opportunities Fund
Nuveen Municipal Credit Opps Fund is a closed-end fund. The fund's objective is to provide a high level of current income exempt from regular U.S. federal income tax and secondarily, total return. It invests in high yielding, low-to medium-quality municipal securities and uses leverage.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.